A growing body of evidence suggests that the vascular actions of Ang-(1-7) appear to involve increased production of nitric oxide (NO), an important vasodilator, through the activation of MasR, thus indicating the involvement of the MasR in preventing endothelial dysfunction. However, it is unknown whether the MasR could be involved in the progression of the next step in atherosclerosis, neo-intimal formation. To determine whether the deletion of the MasR is involved in the development of intimal thickening in an in vitro model. Mice [three background controls (C57Bl/6) and 3 MasR (-/-)] were killed and the aortas excised and cleaned of connective tissue and cut into 3 mm rings. Rings were placed in an organ culture medium for 5 weeks, embedded in paraffin, cut at 5 μm and stained with haematoxylin and eosin and Masson's trichrome. In addition, aortic reactivity was measured in organ baths. After 5 weeks of culture, the intima:media ratio increased in the aortas from MasR (-/-) mice compared to the control group by 4.5-fold (P < 0.01). However, no significant difference in nuclei area count (cell proliferation) between the MasR (-/-) mice and control group was observed (0.87 ± 0.29% vs. 0.94 ± 0.18%, respectively, P = ns). Functional studies showed only a minor vasoconstrictive and full vasodilative response. This study shows that the deletion of the MasR causes marked increase in the aortic intima:media ratio, which is not due to generalized cellular proliferation. These results provide a functional role for the MasR in atherogenesis.

Department of Cardiovascular Diseases International Clinical Research Center St Anne's University Hospital and Masaryk University Brno Czech Republic

Department of Medicine University of Melbourne Austin Health Heidelberg Vic Australia

Max Delbrück Center for Molecular Medicine Berlin Buch Germany

The Centre for Chronic Disease Prevention and Management Western CHRE Victoria University St Albans Vic Australia

Zobrazit více v PubMed

Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin. Immunol. 2010;134:33–46. PubMed

Barter PJ, Nicholls S, Rye KA, Anantharamaiah G, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ. Res. 2004;95:764–772. PubMed

Cable DG, Caccitolo JA, Caplice N, et al. The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation. 1999;100:II392–II396. PubMed

Cogolludo A, Moreno L, Bosca L, Tamargo J, Perez-Vizcaino F. Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction role of protein kinase Cζ. Circ. Res. 2003;93:656–663. PubMed

Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109:III27–III32. PubMed

Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution, signalling and function. Clin. Sci. 2001;100:481–492. PubMed

George AJ, Thomas WG, Hannan RD. The renin–angiotensin system and cancer: old dog, new tricks. Nat. Rev. Cancer. 2010;10:745–759. PubMed

Gunnett CA, Berg DJ, Faraci FM. Vascular effects of lipopolysaccharide are enhanced in interleukin-10–deficient mice. Stroke. 1999;30:2191–2196. PubMed

Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM. Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension. 1992;19:II49. PubMed

Kucharewicz I, Pawlak R, Matys T, Pawlak D, Buczko W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7) Hypertension. 2002;40:774–779. PubMed

Lamping KG, Faraci FM. Role of sex differences and effects of endothelial NO synthase deficiency in responses of carotid arteries to serotonin. Arterioscler. Thromb. Vasc. Biol. 2001;21:523–528. PubMed

Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA. The endothelium-dependent vasodilator effect of the nonpeptide Ang (1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J. Cardiovasc. Pharmacol. 2005;46:274–279. PubMed

Peiró C, Vallejo S, Gembardt F, et al. Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J. Hypertens. 2007;25:2421–2425. PubMed

Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB., Sr Carotid-wall intima–media thickness and cardiovascular events. N. Engl. J. Med. 2011;365:213–221. PubMed PMC

Santos RA, e Silva ACS, Maric C, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl Acad. Sci. USA. 2003;100:8258–8263. PubMed PMC

Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension. 1999;34:950–957. PubMed

Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E–deficient mice. Arterioscler. Thromb. Vasc. Biol. 2010;30:1606–1613. PubMed

Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, Santos SS, Luft FC, Bader M, Gross V, Alenina N, Santos RA. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension. 2008;51:574–580. PubMed

Zhang F, Hu Y, Xu Q, Ye S. Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS One. 2010;5:e12323. PubMed PMC